Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Inotropes acute

Positive inotropes 206 Novel positive inotropes 207 Acute inotropes and vasopressors 207 Diuretics 210 Vasodilators 210... [Pg.193]

The toxic effects of propranolol are related to its negative inotropic and chronotropic properties, which can lead to sinus bradycardia and hypotension. These complications should be treated with an acute inotrope such as dopamine or dobutamine. [Pg.203]

Table 12.4 Acute Inotropes and vasopressora mechanisms of action ... Table 12.4 Acute Inotropes and vasopressora mechanisms of action ...
Congestive heart failure P-Agonists Acute inotropic support Dobutamine, Orciprenaline... [Pg.133]

Treatment of acute heart failure targets relief of congestion and optimization of cardiac output utilizing oral or intravenous diuretics, intravenous vasodilators, and when appropriate, inotropes. [Pg.33]

Another mechanism to maintain CO when contractility is low is to increase heart rate. This is achieved through sympathetic nervous system (SNS) activation and the agonist effect of norepinephrine on P-adrenergic receptors in the heart. Sympathetic activation also enhances contractility by increasing cytosolic calcium concentrations. SV is relatively fixed in HF, thus HR becomes the major determinant of CO. Although this mechanism increases CO acutely, the chronotropic and inotropic responses to sympathetic activation increase myocardial oxygen demand, worsen underlying ischemia, contribute to proarrhythmia, and further impair both systolic and diastolic function. [Pg.35]

Current data suggest little benefit on clinical outcomes beyond symptom relief for calcium channel blockers in the setting of ACS.43 Moreover, the use of first-generation shortacting dihydropyridines, such as nifedipine, should be avoided because they appear to worsen outcomes through their negative inotropic effects, induction of reflex sympathetic activation, tachycardia, and increased myocardial ischemia.43 Therefore, calcium channel blockers should be avoided in the acute management of MI unless there is a clear symptomatic need or a contraindication to p-blockers. [Pg.99]

Because of their negative inotropic effects, /J-blockers should be started in very low doses with slow upward dose titration to avoid symptomatic worsening or acute decompensation. Patients should be titrated to target doses when possible to provide maximal survival benefits. However, even lower doses have benefits over placebo, so any dose is likely to provide some benefit. [Pg.100]

FIGURE 8-2. General treatment algorithm for acute decompensated heart failure (ADHF) based on clinical presentation. IV vasodilators that may be used include nitroglycerin, nesiritide, or nitroprusside. Metolazone or spironolactone may be added if the patient fails to respond to loop diuretics and a second diuretic is required. IV inotropes that may be used include dobutamine or milrinone. (D/C, discontinue HF, heart failure SBP, systolic blood pressure.) (Reprinted and adapted from J Cardiac Fail, Vol 12, pages el-el 22, copyright 2006, with permission from Elsevier.)... [Pg.105]

HT4 receptors are also present in the pig and human hearts, primarily located in the atrium [9]. Experiments showed that stimulation of these receptors can result in tachycardia and can trigger positive inotropic effects. Moreover, it has been demonstrated that the 5-HT4 receptor is present in the human detrusor muscle and facilitates a cholinergic mechanism which may lead to increased bladder contractions [10]. Finally, acute (but not repeated) stimulation of 5-HT4 receptors present on the human adrenal cortex has been reported to trigger the release of corticosterone and aldosterone [11]. [Pg.197]

A dose of 7.0 /ig/kg of indolidan (i.v. administration) resulted in a 50% increase in contractility in anaesthetized dogs. A selective inotropic response has been observed with conscious dogs upon oral administration of 25 ngj kg of (23). The haemodynamic profile of (23) has been evaluated in anaesthetized dogs [78]. The acute and subchronic toxicology of indolidan has been studied (rats, dogs) [79]. [Pg.148]

Acute Ml Use digoxin with caution in patients with acute Ml. The use of inotropic drugs in some patients in this setting may result in undesirable increases in myocardial oxygen demand and ischemia. [Pg.407]

Noradrenaline and adrenaline are the classic catecholamines and neurotransmitters in the sympathetic nervous system. Noradrenaline stimulates the following subtypes of adrenoceptors P, a, U2. It has positive inotropic and chronotropic activities as a result of /3i-receptor stimulation. In addition, it is a potent vasoconstrictor agent as a result of the stimulation of both subtypes (ai,a2) of a-adrenoceptors. After intravenous infusion, its effects develop within a few minutes, and these actions disappear within 1-2 minutes after stopping the infusion. It may be used in conditions of acute hypotension and shock, especially in patients with very low vascular resistance. It is also frequently used as a vasoconstrictor, added to local anaesthetics. Adrenaline stimulates the following subtypes of adrenoceptors /3i, P2, oil, 0L2. Its pharmacological profile greatly resembles that of noradrenaline (see above), as well as its potential applications in shock and hypotension. Like noradrenaline, its onset and duration of action are very short, as a result of rapid inactivation in vivo. Both noradrenaline and adrenaline may be used for cardiac stimulation. Their vasoconstrictor activity should be kept in mind. A problem associated with the use of /3-adrenoceptor stimulants is the tachyphylaxis of their effects, explained by the /3-adrenoceptor downregulation, which is characteristic for heart failure. [Pg.338]

Dopamine itself has long been used as an inotropic agent in acute treatment of congestive heart failure. Both that compound and a number of its analogues have a positive action on contractility as a consequence of their adrenergic agonist activity. [Pg.496]

Digoxin remains the mainstay of treatment for patients with chronic myocardial failure. Other drugs with inotropic and/or vasodilator properties, including the catecholamines and phosphodiesterase III (PDE) inhibitors, are used in the treatment of acute cardiac failure. The inotropic actions of most of these drugs result from a direct or indirect elevation of [Ca2-i-]i (intracellular Ca2+ concentration). This acts as a trigger for a process which leads to increased contractile state and cardiac contraction (Figures 8.3 and 8.4). Myofilament calcium sensitisers increase the sensitivity of contractile proteins to calcium. Some newer drugs, such as vesnarinone, have multiple mechanisms of action. [Pg.149]

This drug is only approved for oral administration in some countries. It is effective for conversion of atrial flutter or fibrillation or ischaemia-induced ventricular arrhythmias. It has significant anticholinergic properties (10% of the potency of atropine) that can offset its direct depressant effects on sinus and AV nodes. It has a pronounced negative inotropic effect and should be administered with caution to patients with a history of congestive heart failure. For acute treatment of perioperative arrhythmias it is given intravenously 0.2 mg-kg-1 over 10-15 min, then 0.2 mg-kg-1 over the next 45 min and a maintenance infusion of 0.4 mg-kg-l-h-1. [Pg.159]

Dobutamine1 Activates adenylyl cyclase, increasing myocardial contractility Positive inotropic effect Cardiogenic shock, acute heart failure IV requires dose titration to desired effect... [Pg.192]

Heart failure is a syndrome with many causes that may involve either ventricle or both. Cardiac output is usually below the normal range. Systolic dysfunction, with reduced cardiac output and significantly reduced ejection fraction (< 45%), is typical of acute failure, especially that resulting from myocardial infarction. Diastolic dysfunction often occurs as a result of hypertrophy and stiffening of the myocardium, and although cardiac output is reduced, ejection fraction may be normal. Heart failure due to diastolic dysfunction does not usually respond optimally to positive inotropic drugs. [Pg.303]

Paradoxically, these agents—not positive inotropic drugs—are the first-line therapies for chronic heart failure. The drugs most commonly used are diuretics, ACE inhibitors, angiotensin receptor antagonists, aldosterone antagonists, and blockers (Table 13-1). In acute failure,... [Pg.310]

Uses Acute CHF, ischemic cardiomyopathy Action Inotrope w/ vasodilator Dose IV bolus 0.75 mg/kg over 2-3 min maint 5-10 mcg/kg/min, 10 mg/kg/d max i if CrCl <10 mL/min Caution [C, ] Contra Bisulfite allergy Disp Inj SE Monitor fluid, electrolyte, renal changes Interactions Diuretics cause significant hypovolemia T effects OF cardiac glycosides EMS Avoid diuretic use, can cause profound hypovolemia incompatible w/ dextrose solns monitor ECG for hypokalemia (flattened T waves) OD May cause profound hypotension use IV fluids w/ caution d/t fluid buildup in lungs, pressors may be used... [Pg.191]

Dopamine and dobutamine are sometimes used to stimulate the heart in cases of acute or severe heart failure (see Chapter 20). Dopamine and dobutamine exert a fairly specific positive inotropic effect, presumably through their ability to stimulate beta-1 receptors on the myocardium.60 Other beta-1 agonists (epinephrine, prenalterol, etc.) will also increase myocardial contractility, but most of these other beta-1 agonists will also increase heart rate or have other side effects that prevent their use in congestive heart failure. Dopamine and dobutamine are usually reserved for patients with advanced cases of congestive heart failure who do not respond to other positive inotropic drugs (e.g., digitalis).6,72... [Pg.339]


See other pages where Inotropes acute is mentioned: [Pg.205]    [Pg.205]    [Pg.207]    [Pg.135]    [Pg.479]    [Pg.205]    [Pg.205]    [Pg.207]    [Pg.135]    [Pg.479]    [Pg.140]    [Pg.22]    [Pg.48]    [Pg.51]    [Pg.58]    [Pg.117]    [Pg.95]    [Pg.73]    [Pg.191]    [Pg.86]    [Pg.338]    [Pg.439]    [Pg.156]    [Pg.189]    [Pg.208]    [Pg.301]    [Pg.306]    [Pg.314]    [Pg.73]    [Pg.98]    [Pg.339]    [Pg.212]    [Pg.288]   


SEARCH



Heart failure, acute inotropic agents

Inotropes

Inotropism

© 2024 chempedia.info